The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending booster shots.

Significant delays in core FDA functions — such as approving amendments to clinical trials and guiding companies through ...

The Global Active Pharmaceutical Ingredients Market achieved a valuation of $209.80 Billion in 2024 and is anticipated to ...

The Global Generic Drugs Market achieved a valuation of $487.21 Billion in 2024 and is anticipated to exceed $898 Billion by ...